← SynDRA
LOTEPREDNOL ETABONATE
SynDRA canonical compound SYN0023242 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | NR3C1 |
|---|
| Mechanism of action | Glucocorticoid receptor agonist |
|---|
| Indication | conjunctivitis |
|---|
| Disease area | ophthalmology |
|---|
All known targets
- NR3C1
- ESRRA; ESRRB; ESRRG
Mechanisms of action (all sources)
- Phospholipase inhibitor
- NR3C1 AGONIST
- Modulator
Drug classes
- Corticosteroid Hormone Receptor Agonists
- Corticosteroid
- Anti-Allergic Agents
ATC classes
- S01B · ANTIINFLAMMATORY AGENTS
Cross-references
Synonyms
- lenoxin
- lotemax
- Loteprednol
- CDDD-5604
- CDDD5604
- HGP-1
- KPI-121
- P-5604
- Alrex
- Eysuvis
- Inveltys
- Lotemax
- Lotemax sm
- Loteprednol etabonate component of zylet
- Locort
- Loteflam
- Loterox
- IDR-90102
- IDR-90103
- Lotemax (TN)
- Alrex, Lotemax, Loteprednol etabonate
- Loteprednol etabonate (JAN/USAN)
- Chloromethyl 17alpha-[(ethoxycarbonyl)oxy]-11beta-hydroxy-3-oxoandrosta-1,4-diene-17beta-carboxylate
- Chloromethyl (8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate
- loteprednol
- EYSUVIS
- ZYLET COMPONENT LOTEPREDNOL ETABONATE
- YEH1EZ96K6
- HGP 1
- P 5604
- CDDD 5604
- Airex
- CHEBI:31784
- DTXCID0026468
- Lotemax SM
- CEHOAC
- Etabonate, Loteprednol
Reported adverse events
Look up LOTEPREDNOL ETABONATE in the interactive SynDRA portal →